Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Oligodendrocyte Progenitor Cell Culture From Human Brain

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2008 by Rajavithi Hospital.
Recruitment status was:  Recruiting
Information provided by:
Rajavithi Hospital Identifier:
First received: January 25, 2006
Last updated: August 2, 2008
Last verified: August 2008
Recent developments in the understanding of stem- and progenitor cell differentiation raises hopes that brain damage in chronic neurological diseases may become repaired by systemic or focal transplantation of such cells. Clinical trials of stem- or progenitor cell transplantation in multiple sclerosis are currently premature. The researchers developed a protocol for human oligodendrocyte progenitor cell culture from human brain for the treatment of demyelinating disease.

Condition Intervention Phase
Demyelinating Diseases
Procedure: Oligodendrocyte progenitor cell culture/craniotomy
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Phase 1: Oligodendrocyte Progenitor Cell Culture From Human Brain

Further study details as provided by Rajavithi Hospital:

Primary Outcome Measures:
  • Number of oligodendrocyte progenitor cell differentiation [ Time Frame: one month ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: December 2007
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Progenitor cells from the patinets with Craniotomy with V-P Shunt or ventriculostomy will be collected and cultured.
Procedure: Oligodendrocyte progenitor cell culture/craniotomy
Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply
Other Name: Rajavithi Oligodendrocyte progenitor cell culture protocol

Detailed Description:
Oligodendrocyte progenitor cell line were cultures and will be transplanted into the patient with Multiple sclerosis.

Ages Eligible for Study:   20 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female 20-65 years of age
  • Informed consent
  • Has elective craniotomy surgery

Exclusion Criteria:

  • HIV, hepatitis, and other central nervous system (CNS) infections
  • Dementia, Alzheimer disease, and neurodegenerative disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00283023

Assistant Professor Subsai Kongsaengdao
Bangkok, Thailand, 10400
Sponsors and Collaborators
Rajavithi Hospital
Principal Investigator: Subsai Kongsaengdao, M.D. Division of Neurology, Department of Medicine, Rajavithi Hospital : Thailand
  More Information

Responsible Party: Assistant Professor Subsai Kongsaengdao, Rajavithi Hospital Identifier: NCT00283023     History of Changes
Other Study ID Numbers: RH-CMR-003  RVH-CMR-003 grant 
Study First Received: January 25, 2006
Last Updated: August 2, 2008
Health Authority: Thailand: Ministry of Public Health

Keywords provided by Rajavithi Hospital:
All selective craniotomy

Additional relevant MeSH terms:
Demyelinating Diseases
Nervous System Diseases processed this record on December 02, 2016